Paul T Nghiem

Title: Paul T Nghiem: Innovator in Cancer Research

Introduction

Paul T Nghiem is a prominent inventor based in Redmond, WA (US). He has made significant contributions to the field of cancer research, particularly in the development of targeted therapies for Merkel cell carcinoma. His innovative work has led to advancements in understanding and treating this aggressive form of skin cancer.

Latest Patents

Paul T Nghiem holds a patent for "High affinity Merkel cell polyomavirus T antigen-specific TCRs and uses thereof." This patent provides binding proteins and T cell receptors (TCRs) that exhibit high affinity and specificity against Merkel cell polyomavirus T antigen epitopes. The T cells expressing these high affinity TCRs, along with the nucleic acids encoding them, are designed for use in treating Merkel cell carcinoma.

Career Highlights

Throughout his career, Paul has worked with esteemed institutions such as the Fred Hutchinson Cancer Center and the University of Washington. His research has focused on the intersection of immunology and oncology, leading to breakthroughs in cancer treatment.

Collaborations

Paul T Nghiem has collaborated with notable colleagues, including Aude Georgiana Chapuis and Megan McAfee. These partnerships have fostered a collaborative environment that enhances the research and development of innovative cancer therapies.

Conclusion

Paul T Nghiem's contributions to cancer research and his innovative patent demonstrate his commitment to advancing medical science. His work continues to impact the field and offers hope for improved treatments for patients with Merkel cell carcinoma.